{"organizations": [], "uuid": "d9b92ced41b6ec65882c2e33579b6a0bd58484fa", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-kura-oncology-inc-co-entered-into/brief-kura-oncology-inc-co-entered-into-an-amended-and-restated-sales-agreement-with-cowen-and-company-idUSFWN1QU137", "country": "US", "domain_rank": 408, "title": "BRIEF-Kura Oncology Inc - Co Entered Into An Amended And Restated Sales Agreement With Cowen And Company​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T22:49:00.000+02:00", "replies_count": 0, "uuid": "d9b92ced41b6ec65882c2e33579b6a0bd58484fa"}, "author": "", "url": "https://www.reuters.com/article/brief-kura-oncology-inc-co-entered-into/brief-kura-oncology-inc-co-entered-into-an-amended-and-restated-sales-agreement-with-cowen-and-company-idUSFWN1QU137", "ord_in_thread": 0, "title": "BRIEF-Kura Oncology Inc - Co Entered Into An Amended And Restated Sales Agreement With Cowen And Company​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-kura oncology inc - co", "sentiment": "negative"}, {"name": "cowen and company", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "kura oncology inc", "sentiment": "none"}, {"name": "kura oncology inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "cowen and company​ reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 12, 2018 / 8:51 PM / in 10 minutes BRIEF-Kura Oncology Inc - Co Entered Into An Amended And Restated Sales Agreement With Cowen And Company​ Reuters Staff 1 Min Read March 12 (Reuters) - Kura Oncology Inc: * KURA ONCOLOGY INC - ‍ON MARCH 12, 2018, CO ENTERED INTO AN AMENDED AND RESTATED SALES AGREEMENT WITH COWEN AND COMPANY, LLC - SEC FILING​ * KURA ONCOLOGY-INCREASED MAXIMUM AGGREGATE OFFERING PRICE OF SHARES OF CO'S COMMON STOCK, THAT IS CO MAY OFFER AND SELL FROM $100.0 MILLION TO $160.0 MILLION​ Source text ( bit.ly/2HrCHZZ ) Further company coverage: (Reuters.Brief@thomsonreuters.com)", "external_links": [], "published": "2018-03-12T22:49:00.000+02:00", "crawled": "2018-03-12T23:09:15.002+02:00", "highlightTitle": ""}